Targeting polyamine biosynthesis to stimulate beta cell regeneration in zebrafish

Morgan A Robertson, Leah R Padgett, Jonathan A Fine, Gaurav Chopra, Teresa L Mastracci, Morgan A Robertson, Leah R Padgett, Jonathan A Fine, Gaurav Chopra, Teresa L Mastracci

Abstract

Type 1 diabetes (T1D) is a disease characterized by destruction of the insulin-producing beta cells. Currently, there remains a critical gap in our understanding of how to reverse or prevent beta cell loss in individuals with T1D. Previous studies in mice discovered that pharmacologically inhibiting polyamine biosynthesis using difluoromethylornithine (DFMO) resulted in preserved beta cell function and mass. Similarly, treatment of non-obese diabetic mice with the tyrosine kinase inhibitor Imatinib mesylate reversed diabetes. The promising findings from these animal studies resulted in the initiation of two separate clinical trials that would repurpose either DFMO (NCT02384889) or Imatinib (NCT01781975) and determine effects on diabetes outcomes; however, whether these drugs directly stimulated beta cell growth remained unknown. To address this, we used the zebrafish model system to determine pharmacological impact on beta cell regeneration. After induction of beta cell death, zebrafish embryos were treated with either DFMO or Imatinib. Neither drug altered whole-body growth or exocrine pancreas length. Embryos treated with Imatinib showed no effect on beta cell regeneration; however, excitingly, DFMO enhanced beta cell regeneration. These data suggest that pharmacological inhibition of polyamine biosynthesis may be a promising therapeutic option to stimulate beta cell regeneration in the setting of diabetes.

Keywords: Beta cell; DFMO; difluoromethylornithine; imatinib; islet; ornithine decarboxylase; polyamine biosynthesis; regeneration; type 1 diabetes; zebrafish.

Figures

Figure 1.
Figure 1.
Whole-body development and exocrine pancreas size are unaltered with DFMO treatment. (A) A survival curve of zebrafish embryos treated with DFMO for 3 d (from 4 to 7 dpf). (B) Image of 7 dpf Tg(insa:flag-NTR:cryaa:mCherry);Tg(ptf1a:GFP) double transgenic control, NFP, and DFMO-treated zebrafish embryos. Scale bar = 1 mm. (C) Quantification of pancreas length normalized to whole-body length at 7 dpf. Each experiment was performed at least three times, starting with 15 embryos in each group. One-way ANOVA determined significance; data are represented as mean ± SEM * p < .05, ** p < .01, **** p < .0001. Tx, treatment.
Figure 1.
Figure 1.
Whole-body development and exocrine pancreas size are unaltered with DFMO treatment. (A) A survival curve of zebrafish embryos treated with DFMO for 3 d (from 4 to 7 dpf). (B) Image of 7 dpf Tg(insa:flag-NTR:cryaa:mCherry);Tg(ptf1a:GFP) double transgenic control, NFP, and DFMO-treated zebrafish embryos. Scale bar = 1 mm. (C) Quantification of pancreas length normalized to whole-body length at 7 dpf. Each experiment was performed at least three times, starting with 15 embryos in each group. One-way ANOVA determined significance; data are represented as mean ± SEM * p < .05, ** p < .01, **** p < .0001. Tx, treatment.
Figure 2.
Figure 2.
DFMO treatment enhances beta cell regeneration. (A) Representative immunofluorescence images of insulin- (green) and glucagon- (red) expressing cells in the principal islet of zebrafish embryos from each control and treatment group. Quantification of glucagon-expressing cells (B), insulin+/glucagon+ co-expressing cells (C), and insulin-expressing cells (D) in control and NFP-ablated zebrafish at 4 dpf as well as control, NFP and DFMO-treated zebrafish at 7 dpf. Each experiment was performed at least three times, starting with 15 embryos in each group. One-way ANOVA determined significance; data are represented as mean ± SEM * p < .05, ** p < .01, **** p < .0001. Tx, treatment; gluc, glucagon. Scale bars = 10 µm.
Figure 2.
Figure 2.
DFMO treatment enhances beta cell regeneration. (A) Representative immunofluorescence images of insulin- (green) and glucagon- (red) expressing cells in the principal islet of zebrafish embryos from each control and treatment group. Quantification of glucagon-expressing cells (B), insulin+/glucagon+ co-expressing cells (C), and insulin-expressing cells (D) in control and NFP-ablated zebrafish at 4 dpf as well as control, NFP and DFMO-treated zebrafish at 7 dpf. Each experiment was performed at least three times, starting with 15 embryos in each group. One-way ANOVA determined significance; data are represented as mean ± SEM * p < .05, ** p < .01, **** p < .0001. Tx, treatment; gluc, glucagon. Scale bars = 10 µm.
Figure 3.
Figure 3.
Whole-body development and exocrine pancreas size are unaltered with Imatinib treatment. (A) A survival curve of zebrafish embryos treated with Imatinib for 3 d (from 4 to 7 dpf). (B) Quantification of pancreas length normalized to whole-body length at 7 dpf. Each experiment was performed at least 3 times, starting with 15 embryos in each group. One-way ANOVA determined significance. Data are represented as mean ± SEM ** p < .01, **** p < .0001. Tx, treatment.
Figure 3.
Figure 3.
Whole-body development and exocrine pancreas size are unaltered with Imatinib treatment. (A) A survival curve of zebrafish embryos treated with Imatinib for 3 d (from 4 to 7 dpf). (B) Quantification of pancreas length normalized to whole-body length at 7 dpf. Each experiment was performed at least 3 times, starting with 15 embryos in each group. One-way ANOVA determined significance. Data are represented as mean ± SEM ** p < .01, **** p < .0001. Tx, treatment.
Figure 4.
Figure 4.
Imatinib treatment does not enhance beta cell regeneration. (A) Representative immunofluorescence images of insulin- (green) and glucagon- (red) expressing cells in the principal islet of zebrafish embryos treated with varying doses of Imatinib. (B) Representative immunofluorescence images of insulin- (green) and glucagon- (red) expressing cells in the principal islet of control and NFP-ablated zebrafish embryos at 4 and 7 dpf. Quantification of insulin-expressing cells (C), glucagon-expressing cells (D), and insulin+/glucagon+ co-expressing cells (E) in control and NFP-ablated zebrafish at 4 dpf as well as control, NFP and Imatinib-treated zebrafish at 7 dpf. Each experiment was performed at least 3 times, starting with 15 embryos in each group; one-way ANOVA determined significance; data are represented as mean ± SEM ** p < .01, **** p < .0001. Tx, treatment; gluc, glucagon. Scale bars = 10 µm.
Figure 4.
Figure 4.
Imatinib treatment does not enhance beta cell regeneration. (A) Representative immunofluorescence images of insulin- (green) and glucagon- (red) expressing cells in the principal islet of zebrafish embryos treated with varying doses of Imatinib. (B) Representative immunofluorescence images of insulin- (green) and glucagon- (red) expressing cells in the principal islet of control and NFP-ablated zebrafish embryos at 4 and 7 dpf. Quantification of insulin-expressing cells (C), glucagon-expressing cells (D), and insulin+/glucagon+ co-expressing cells (E) in control and NFP-ablated zebrafish at 4 dpf as well as control, NFP and Imatinib-treated zebrafish at 7 dpf. Each experiment was performed at least 3 times, starting with 15 embryos in each group; one-way ANOVA determined significance; data are represented as mean ± SEM ** p < .01, **** p < .0001. Tx, treatment; gluc, glucagon. Scale bars = 10 µm.

References

    1. Atkinson MA, Roep BO, Posgai A, Wheeler DCS, Peakman M.. The challenge of modulating β-cell autoimmunity in type 1 diabetes. Lancet Diabetes Endocrinol. 2019;7:52–64.
    1. Matthews JB, Staeva TP, Bernstein PL, Peakman M, von Herrath M, Group I-JT. 1 DCTA. Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF type 1 diabetes combination therapy assessment group. Clin Exp Immunol. 2010;160:176–184. doi:10.1111/j.1365-2249.2010.04153.x.
    1. Tersey SA, Colvin SC, Maier B, Mirmira RG. Protective effects of polyamine depletion in mouse models of type 1 diabetes: implications for therapy. Amino Acids. 2014;46:633–642. doi:10.1007/s00726-013-1560-7.
    1. Pegg AE, McCann PP. Polyamine metabolism and function. Am J Physiol. 1982;243:C212–221. doi:10.1152/ajpcell.1982.243.5.C212.
    1. Megosh L, Gilmour SK, Rosson D, AP S, Blessing M, Sawicki JA, O’Brien TG. Increased frequency of spontaneous skin tumors in transgenic mice which overexpress ornithine decarboxylase. Cancer Res. 1995;55:4205–4209.
    1. Giardiello FM, Hamilton SR, Hylind LM, Yang VW, Tamez P, Casero RA. Ornithine decarboxylase and polyamines in familial adenomatous polyposis. Cancer Res. 1997;57:199–201.
    1. Smith MK, Goral MA, Wright JH, Matrisian LM, Morris RJ, Klein-Szanto AJ, Gilmour SK. Ornithine decarboxylase overexpression leads to increased epithelial tumor invasiveness. Cancer Res. 1997;57:2104–2108.
    1. Manni A, Washington S, Griffith JW, Verderame MF, Mauger D, Demers LM, Samant RS, Welch DR. Influence of polyamines on in vitro and in vivo features of aggressive and metastatic behavior by human breast cancer cells. Clin Exp Metastasis. 2002;19:95–105. doi:10.1023/A:1014536909007.
    1. Weiss TS, Bernhardt G, Buschauer A, Thasler WE, Dolgner D, Zirngibl H, Jauch K-W. Polyamine levels of human colorectal adenocarcinomas are correlated with tumor stage and grade. Int J Colorectal Dis. 2002;17:381–387. doi:10.1007/s00384-002-0394-7.
    1. Minois N, Carmona-Gutierrez D, Madeo F. Polyamines in aging and disease. Aging (Albany NY). 2011;3:716–732. doi:10.18632/aging.100361.
    1. Hougaard DM, Nielsen JH, Larsson LI. Localization and biosynthesis of polyamines in insulin-producing cells. Biochem J. 1986;238:43–47. doi:10.1042/bj2380043.
    1. Hougaard DM, Larsson LI. Localization and possible function of polyamines in protein and peptide secreting cells. Med Biol. 1986;64:89–94.
    1. Mastracci TL, Robertson MA, Mirmira RG, Anderson RM. Polyamine biosynthesis is critical for growth and differentiation of the pancreas. Sci Rep. 2015;5:13269. doi:10.1038/srep13269.
    1. Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, Zhu S, Weiss A, Bluestone JA. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci USA. 2008;105:18895–18900. doi:10.1073/pnas.0810246105.
    1. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MWN, Silver RT, Goldman JM, Stone RM, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–2417. doi:10.1056/NEJMoa062867.
    1. Mohammed A, Janakiram NB, Madka V, Ritchie RL, Brewer M, Biddick L, Patlolla JMR, Sadeghi M, Lightfoot S, Steele VE, et al. Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling. Cancer Prev Res (Phila). 2014;7:1198–1209. doi:10.1158/1940-6207.CAPR-14-0176.
    1. Mokhtari D, Welsh N. Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes. Clin Sci. 2009;118:241–247. doi:10.1042/CS20090348.
    1. Curado S, Stainier DYR, Anderson RM. Nitroreductase-mediated cell/tissue ablation in zebrafish: a spatially and temporally controlled ablation method with applications in developmental and regeneration studies. Nat Protoc. 2008;3:948–954. doi:10.1038/nprot.2008.58.
    1. Pictet RL, Clark WR, Williams RH, Rutter WJ. An ultrastructural analysis of the developing embryonic pancreas. Developmental Biology. 1972;29:436–467. doi:10.1016/0012-1606(72)90083-8.
    1. Biemar F, Argenton F, Schmidtke R, Epperlein S, Peers B, Driever W. Pancreas development in zebrafish: early dispersed appearance of endocrine hormone expressing cells and their convergence to form the definitive islet. Developmental Biology. 2001;230:189–203. doi:10.1006/dbio.2000.0103.
    1. Argenton F, Zecchin E, Bortolussi M. Early appearance of pancreatic hormone-expressing cells in the zebrafish embryo. Mechan Deve. 1999;87:217–221. doi:10.1016/S0925-4773(99)00151-3.
    1. Beer RL, Parsons MJ, Rovira M. Centroacinar cells: at the center of pancreas regeneration. Dev Biol. 2016;413:8–15. doi:10.1016/j.ydbio.2016.02.027.
    1. Anderson RM, Delous M, Bosch JA, Ye L, Robertson MA, Hesselson D, Stainier DYR. Hepatocyte growth factor signaling in intrapancreatic ductal cells drives pancreatic morphogenesis. PLoS Genet Internet] 2013. [cited 2020 June1]; 9:e1003650. Available from:
    1. Godinho L, Mumm JS, Williams PR, Schroeter EH, Koerber A, Park SW, Leach SD, Wong RO. Targeting of amacrine cell neurites to appropriate synaptic laminae in the developing zebrafish retina. Development. 2005;132:5069–5079. doi:10.1242/dev.02075.
    1. Bergemann D, Massoz L, Bourdouxhe J, Carril Pardo CA, Voz ML, Peers B, Nifurpirinol: MI. A more potent and reliable substrate compared to metronidazole for nitroreductase-mediated cell ablations. Wound Repair Regen. 2018;26:238–244. doi:10.1111/wrr.12633.
    1. Curado S, Anderson RM, Jungblut B, Mumm J, Schroeter E, Stainier DYR. Conditional targeted cell ablation in zebrafish: A new tool for regeneration studies. Developmental Dynamics. 2007;236:1025–1035. doi:10.1002/dvdy.21100.
    1. Ye L, Robertson MA, Hesselson D, Stainier DYR, Anderson RM. Glucagon is essential for alpha cell transdifferentiation and beta cell neogenesis. Development. 2015;142:1407–1417. doi:10.1242/dev.117911.
    1. Pisharath H, Rhee JM, Swanson MA, Leach SD, Parsons MJ. Targeted ablation of beta cells in the embryonic zebrafish pancreas using E. coli nitroreductase. Mechanisms of Development. 2007;124:218–229. doi:10.1016/j.mod.2006.11.005.
    1. Kulkarni AA, Conteh AM, Sorrell CA, Mirmira A, Tersey SA, Mirmira RG, Linnemann AK, Anderson RM. An in vivo zebrafish model for interrogating ros-mediated pancreatic β-cell injury, response, and prevention [Internet]. Oxid Med Cell Longevity. 2018. [cited 2020 June16];2018:e1324739. Available from: .
    1. Helker CSM, Mullapudi S-T, Mueller LM, Preussner J, Tunaru S, Skog O, Kwon H-B, Kreuder F, Lancman JJ, Bonnavion R, et al. A whole organism small molecule screen identifies novel regulators of pancreatic endocrine development. Development. 2019;146; dev172569.
    1. Tsuchiya M, Taniguchi S, Yasuda K, Nitta K, Maeda A, Shigemoto M, Tsuchiya K. Potential roles of large mafs in cell lineages and developing pancreas. Pancreas. 2006;32:408–416. doi:10.1097/01.mpa.0000220867.64787.99.
    1. Thorel F, Népote V, Avril I, Kohno K, Desgraz R, Chera S, Herrera PL. Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. Nature. 2010;464:1149–1154. doi:10.1038/nature08894.
    1. PubChem . Eflornithine [Internet]; [cited 2020 June1]; Available from:
    1. PubChem . Imatinib [Internet]; [cited 2020 June1]; Available from:
    1. Ye L, Robertson MA, Mastracci TL, Anderson RM. An insulin signaling feedback loop regulates pancreas progenitor cell differentiation during islet development and regeneration. Dev Biol. 2016;409:354–369. doi:10.1016/j.ydbio.2015.12.003.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj